REGN

801.01

1.39% -11.26

Handel nachbörslich: 801.01

Regeneron Pharmaceuticals Inc (REGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt REGN? Forum Prognose

Schlusskurs vom Vortag:

$812.27

Offen:

$805.81

24-Stunden-Volumen:

1.05M

Relative Volume:

1.06

Marktkapitalisierung:

$84.19B

Einnahmen:

$14.25B

Nettoeinkommen (Verlust:

$4.58B

KGV:

19.18

EPS:

41.7701

Netto-Cashflow:

$3.88B

1W Leistung:

+3.78%

1M Leistung:

+13.90%

6M Leistung:

+46.24%

1J Leistung:

+9.19%

1-Tages-Spanne:

$800.68

$816.99

1-Wochen-Bereich:

$753.20

$816.99

52-Wochen-Spanne:

$476.49

$816.99

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Firmenname

Regeneron Pharmaceuticals Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (620)

Telefon

(914) 847-7000

Adresse

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Mitarbeiter

15,207

Twitter

@regeneron

Nächster Verdiensttermin

2025-08-01

Neueste SEC-Einreichungen

REGN's Discussions on Twitter

Vergleichen Sie REGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REGN Regeneron Pharmaceuticals Inc	801.01	85.37B	14.25B	4.58B	3.88B	41.77
VRTX Vertex Pharmaceuticals Inc	469.68	122.84B	11.74B	3.68B	3.34B	14.19
ALNY Alnylam Pharmaceuticals Inc	399.40	55.82B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	795.57	50.67B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	170.27	37.54B	447.02M	-1.18B	-906.14M	-6.1812

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-07	Hochstufung	BofA Securities	Underperform → Buy
2025-12-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Eingeleitet	HSBC Securities	Buy
2025-11-24	Fortgesetzt	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Perform
2025-08-14	Eingeleitet	Rothschild & Co Redburn	Buy
2025-06-30	Herabstufung	Argus	Buy → Hold
2025-05-30	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-05-14	Hochstufung	Citigroup	Neutral → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-02-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-01-16	Herabstufung	UBS	Buy → Neutral
2024-12-10	Fortgesetzt	BofA Securities	Underperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-09-24	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-12	Eingeleitet	Bernstein	Outperform
2024-01-12	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-08-21	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-21	Bestätigt	Oppenheimer	Perform
2023-06-28	Herabstufung	Canaccord Genuity	Buy → Hold
2023-03-27	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-24	Hochstufung	Jefferies	Hold → Buy
2023-03-23	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-01-30	Hochstufung	Cowen	Market Perform → Outperform
2023-01-20	Hochstufung	JP Morgan	Neutral → Overweight
2022-10-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-10-17	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-09	Hochstufung	Jefferies	Underperform → Hold
2022-09-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2022-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2022-01-03	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-12-15	Herabstufung	Bernstein	Outperform → Mkt Perform
2021-12-09	Fortgesetzt	Wells Fargo	Overweight
2021-12-07	Fortgesetzt	Cowen	Market Perform
2021-12-06	Eingeleitet	Goldman	Buy
2021-11-19	Fortgesetzt	BMO Capital Markets	Outperform
2021-11-05	Herabstufung	The Benchmark Company	Buy → Hold
2021-06-29	Eingeleitet	H.C. Wainwright	Buy
2021-01-25	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Hochstufung	The Benchmark Company	Hold → Buy
2021-01-08	Hochstufung	Citigroup	Neutral → Buy
2020-10-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2020-07-09	Hochstufung	SunTrust	Hold → Buy
2020-05-26	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-04-28	Herabstufung	Citigroup	Buy → Neutral
2020-04-17	Hochstufung	The Benchmark Company	Hold → Buy
2020-04-08	Eingeleitet	The Benchmark Company	Hold
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-02-26	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-02-25	Hochstufung	Jefferies	Hold → Buy
2020-02-11	Hochstufung	Argus	Hold → Buy
2019-12-24	Eingeleitet	Raymond James	Mkt Perform
2019-12-16	Herabstufung	Evercore ISI	Outperform → In-line
2019-12-13	Hochstufung	Credit Suisse	Neutral → Outperform
2019-11-12	Eingeleitet	SunTrust	Hold
2019-11-07	Hochstufung	Citigroup	Neutral → Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Neutral
2019-09-23	Hochstufung	Guggenheim	Neutral → Buy

Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

01:19 AM

Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News - GuruFocus

01:19 AM

12:54 PM

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial - MarketBeat

12:54 PM

12:02 PM

Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Benzinga

12:02 PM

08:07 AM

Noesis Capital Mangement Corp Has $11.90 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

08:07 AM

07:07 AM

KLP Kapitalforvaltning AS Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:07 AM

06:49 AM

MassMutual Private Wealth & Trust FSB Buys 1,267 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:49 AM

02:09 AM

Diabetic Retinopathy Market to Witness Remarkable Growth With - openPR.com

02:09 AM

Jan 07, 2026